Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Inventory (2024 - 2025)

Outlook Therapeutics (OTLK) has disclosed Inventory for 2 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 11.21% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 11.21% increase, with the full-year FY2025 number at $3.3 million, changed N/A from a year prior.
  • Inventory was $3.5 million for Q4 2025 at Outlook Therapeutics, up from $3.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $4.1 million in Q2 2025 to a low of $3.1 million in Q4 2024.